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Abstract A 32-year-old male developed neuropsychiatric
symptoms 2 weeks after starting mefloquine 250 mg/week
for malaria prophylaxis. He continued to take the medi-
cation for the next 4 months. Initial symptoms included
vivid dreams and anxiety, as well as balance problems.
These symptoms persisted and progressed over the next
4 years to include vertigo, emotional lability, and poor
short-term memory, which have greatly affected his per-
sonal and professional life. An extensive evaluation
revealed objective evidence supporting a central vestibu-
lopathy. These symptoms have been unresponsive to
pharmacologic therapy and psychotherapy. A Naranjo
assessment score of 6 was obtained for his initial symp-
toms, indicating a probable adverse drug reaction to
mefloquine given the relationship between the clinical
picture and drug exposure.
Key Points
Melfoquine-induced neuropsychiatric symptoms can
be severely life debilitating.
Given the overlapping symptoms of post-traumatic
stress disorder and mefloquine toxicity, it can be
challenging to distinguish between the two
diagnoses.
Melfoquine toxicity can persist for several years
after exposure has been discontinued, with little to
no abatement in symptoms over time.
Case Description
A 32-year-old male United States military service member
was referred to the Walter Reed National Military Medical
Center (WRNMMC) Toxicology and Clinical Pharmacol-
ogy Clinic for further evaluation of chronic neuropsychi-
atric symptoms. The patient was in his usual state of health
until 2 weeks after the initiation of mefloquine 250 mg/
week for malaria prophylaxis at the start of a 6- month
deployment to East Africa at the end of 2009. Compliance
with prophylaxis was ensured by the medical corpsmen
who witnessed the weekly medication administration as
directed by the ship’s Commanding Officer. The patient did
not receive the Medication Guide or Information Wallet
Card, and his initial symptoms included anxiety and vivid
dreams. Within 2 months of the deployment the patient
developed a sense of disequilibrium, as well as episodes of
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confusion. He continued to take mefloquine for the
4-month duration of the deployment, as prescribed. Aside
from a 4-day-long febrile illness, for which he tested
negative for malaria, he had no other medical problems
during the deployment. He discussed the vivid dreams with
his medic and was instructed to continue taking the
mefloquine. He attributed the disequilibrium to being
onboard a ship and felt that the heightened anxiety was a
byproduct of being deployed. Neither symptom was dis-
cussed with his medic. He primarily stayed on a ship the
entire deployment and did not partake of any local food or
water and denies any significant environmental exposures
during this time. However, during port stops he did report
drinking alcohol while taking mefloquine. Four months
into the deployment, the patient experienced a traumatic
event (enemy gun fire). The patient reported that his
symptoms remained constant after the traumatic event and
did not change until he came home from deployment
2 months later.
As soon as he returned home from deployment, 6
months after starting mefloquine, the patient and his wife
noted increased emotional lability, typically manifesting as
anger and irritability. He also endorsed difficulty concen-
trating, a decreased interest in most activities, persistent
short-term memory problems and word-finding difficulties.
In addition, right after disembarking from his ship, he had
persistent ‘sea legs’ that became more episodic over the
course of a few months. At the time of his visit to
WRNMMC, the episodes of vertigo occurred four to five
times per day and lasted approximately 20–30 min. He
described the sensation as ‘‘everything in front of me is
moving’’. Closing his eyes improved these vertiginous
symptoms. The patient reported knowing when symptoms
were coming but denied any accompanying sweating, heart
rate change, chest pain or nausea. He also reported having a
constant dizziness that he described as ‘‘inside my head is
spinning’’. This symptom worsens when changing position
or when running. He routinely stumbles when walking and
has fallen down the stairs once. Prior to his deployment, the
patient was a marathon runner but is now unable to run due
to disequilibrium and vertigo.
These symptoms have led to significant marital prob-
lems, as well as self-reported concerns over his parenting
abilities. The patient has needed significant support from
his surrounding staff to function at his job due to his
continued poor short-term memory. At the time of his
clinic visit, the vivid dreams persisted, as well as night-
mares and recurrent insomnia. His nightmares are rarely
related to his deployment experiences. Aside from three
visits to a mental health clinic for anger-coping strategies,
the patient has not sought medical attention for these
symptoms over the previous 4 years.
Five months prior to his visit to WRNMMC, during a
visit with a provider for a febrile illness, the patient men-
tioned the neuropsychiatric symptoms and was referred to
the mental health clinic for further evaluation. He was ini-
tially diagnosed with anxiety disorder and was started on
prazosin, which was stopped due to ineffectiveness. He was
also tried on clonazepam and lorazepam, which were dis-
continued due to an increase in vertiginous symptoms and
ineffectiveness, respectively. He underwent extensive neu-
ropsychiatric testing; however, due to a perceived lack of
effort and inability to focus, he failed the performance-based
validity tests, making interpretation of the results difficult.
After 3 months of psychotherapy and pharmacotherapy, his
psychiatrist also diagnosed him with post-traumatic stress
disorder (PTSD). This was primarily due to two episodes of
heightened anxiety after being in close proximity to people
believed to be from Somalia, which was one of the areas of
operations from his previous deployment. At the time of this
clinic visit, the patient was regularly seeing a psychiatrist
and psychologist and had just started cognitive behavioral
therapy. His medications included meclizine, venlafaxine,
diazepam and clonidine. Aside from an improvement in his
depressive symptoms, the patient reported no improvement
in his recurrent balance or nightmare episodes since starting
pharmacotherapy.
Review of symptoms was positive for daily parietal
headaches that sometimes refer occipitally, typically last a
few hours, and resolve without pharmacotherapy. The
patient denied any accompanying photophobia, phono-
phobia, nausea, blurry vision or proceeding aura, and also
reported having recurrent febrile episodes that lasted for
2–3 days, every 3–4 months, since his deployment. These
episodes resolved without medical intervention. The
patient denied any associated symptoms with the fever,
including pharyngitis or aphthous ulcers. He has also had
enlarged, painless cervical lymph nodes for the past year,
and has denied any weight loss, skin infections, sore
throats, and exposure to cats or other animals. He previ-
ously had an extensive negative workup for these, includ-
ing a complete blood count (CBC), chest x-ray,
mononucleosis screen and malaria smear. Two neck
ultrasounds, 6 months apart, suggested reactive lym-
phadenopathy. Additionally, antinuclear antibodies (ANA),
folate, vitamin B12, brain magnetic resonance imaging
(MRI) and internal auditory canal MRI were all normal.
Additional past medical history is significant for recur-
rent corneal abrasions of unknown etiology occurring
approximately two to three times per year since 2009. The
patient denied use of any other medications, dietary sup-
plements or herbal remedies at the time the symptoms
started or since. He reported no history of head trauma or
mental health disorders.
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The patient denied any significant family medical his-
tory, including mental health disorders or a history of
periodic fevers.
The patient has lived in three different, recently built
homes since returning from deployment. His only hobby is
fishing; he does eat the fish that he catches. The patient
denied any work or home activities that involved chemical
fumes or vapors or use of industrial chemicals. He reported
heavy alcohol use upon returning from deployment as a
means of coping with his behavioral changes. However,
after a few months, the patient was able to self-limit his
intake and now drinks socially. He denied a history of
alcohol withdrawal symptoms and use of any illicit drugs
or nicotine products.
On examination, the patient was a well-dressed, articu-
late man who responded appropriately to all questions. He
did appear jittery and frequently had to check his smart-
phone for answers to several medical history questions.
Significant positive findings on his physical examination
included head and neck flushing and mildly enlarged right
posterior cervical and submandibular chain lymph nodes,
with one smooth, mobile, non-tender node on the cervical
chain measuring approximately 1 cm in diameter. His
neurological examination was normal except for loss of
balance while getting up from a seated position and during
the tandem walk.
The patient underwent evaluations by the Infectious
Diseases, Otolaryngology, Audiology and Neurology ser-
vices. His initial workup included negative urine and blood
heavy metal screens (copper, arsenic, mercury, lead, cad-
mium), and illicit drug urine screen, normal inflammatory
markers, and CBC, thyroid, parathyroid, liver and kidney
function labs. He also had a normal 24-h holter monitor.
Additional laboratory examination revealed normal values
for human chorionic gonadotropin (hCG), carcinoembry-
onic antigen (CEA), vasoactive intestinal polypeptide
(VIP), catecholamines and a-fetoprotein (AFP). His
infectious disease workup included negative labs for
malaria, histoplasmosis, blastomycosis, HIV, tuberculosis,
bartonella, Epstein–Barr Virus (EBV), syphilis, Lyme
disease, cytomegalovirus (CMV), babesiosis, and chronic
Q fever, and microscopy was without evidence of parasites
in his blood. He also underwent a fine needle aspiration of
the enlarged cervical lymph node, and the pathology was
consistent with benign lymphoid tissue. It was the opinion
of both the infectious diseases and otolaryngology con-
sultants that the lymphadenopathy was likely reactive and
benign, and no clear infectious etiology could be identified
to explain the febrile episodes.
Positive findings in the patient’s initial laboratory
evaluation included an elevated histamine level of 4.75 ng/
mL (normal \1.00), and low serotonin (9 ng/mL
[21–321 ng/mL]) and thiamine levels (42.6 nmol/L
[66.5–200 nmol/L]). As a result of the elevated histamine
and flushing seen on examination, a subsequent workup to
rule out a carcinoid tumor demonstrated normal 5-hy-
droxyindoleacetic acid (5-HIAA), chromogranin A, gastrin,
adrenocorticotropic hormone (ACTH) and calcitonin
levels. A repeat histamine level was also normal, as was an
octreotide scan. Due to the elevated histamine and
decreased serotonin, the patient’s methylenetetrahydrofo-
late (MTHFR) gene was tested and showed a single C677T
mutation. The patient also had a normal homocysteine
level. He was started on oral thiamine replacement (50 mg
twice daily), with no improvement in his symptoms.
Vestibular testing by audiology showed no evidence of
peripheral vestibulopathy. An MRI of the internal auditory
canals was unremarkable. Rotary chair testing results
showed rare findings of hyperactive vestibulo-ocular reflex
(VOR) gains and an abnormally low VOR phase. These
findings were reported to be consistent with migraines,
motion sickness or a central vestibulopathy. The patient
was referred for vestibular rehabilitation therapy.
In follow-up, the patient has been medically discharged
from the military. Four and a half years after initial
mefloquine exposure, he is still experiencing significant
short-term memory problems and is seeing a speech ther-
apist to aid with techniques to improve his memory and
assist in activities of daily living. As a result of his short-
term memory deficiency, the patient is only able to work
part-time. He sleeps approximately 3–4 h per night and still
regularly has vivid dreams and nightmares. He has multiple
episodes of vertigo per week that force him to lie down and
close his eyes. His constant dizziness has also persisted and
he has reported several more falls while walking. His
behavioral and psychological issues continue, with
depressed mood, lack of motivation, restlessness, anxiety
and emotional lability. He sees a behavioral therapist
weekly and has discontinued all prescribed medications.
He currently takes only vitamins and fish oil.
Discussion
Mefloquine was first discovered at the Walter Reed Army
Institute of Research in the 1970s and was approved by the
US FDA in 1989, under the tradename Lariam [1].
Although the original product insert alluded to the potential
for neuropsychiatric side effects, it would be another 10–15
years before the full scope of toxicity, when used for
malaria prophylaxis, was demonstrated in randomized
control trials [1, 2]. In 2003, the FDA mandated that all
patients prescribed mefloquine also receive a patient
medication guide. In 2013, the FDA approved an updated
and more stringent mefloquine drug label that included a
boxed warning which, along with the patient medication
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guide, included information that neurologic and psycho-
logic side effects of mefloquine may persist long after the
drug has been discontinued, and may become permanent
[3, 4]. Due to the increasing awareness of these neu-
ropsychiatric side effects, the United States military rele-
gated mefloquine to a third-line medication behind
doxycycline and Malarone (atovaquone-proguanil) for
prophylaxis in areas of chloroquine-resistant malaria, such
as Afghanistan [5]. Consequently, from 2008 to 2013, the
use of mefloquine in the military has decreased dramati-
cally [6].
Mefloquine is an antimalarial that can be taken as
treatment or as a prophylactic medication. Due to its long
half-life, it is prescribed for once weekly administration for
prophylactic use against malaria. Neuropsychiatric side
effects attributed to mefloquine use range from common
mild symptoms of insomnia, anxiety, mood changes,
headaches, dizziness or vertigo to more severe and rare
psychoses, violent behaviors, seizures, neuropathies and
even suicide. Case reports describe a wide range of these
and other symptoms, including symptoms of bipolar dis-
order, peripheral polyneuropathy, paranoid psychosis and
suicide [7–11]. Rates of neuropsychiatric symptoms from
prospective studies have ranged anywhere from 8 to 77 %
[12–15].
Known risk factors for these neuropsychiatric side
effects include a history of neuropsychiatric disorders,
female sex, no previous mefloquine exposure and low body
mass index [16]. This patient, aside from this being his first
exposure to mefloquine, had none of the purported risk
factors for neuropsychiatric adverse drug effects.
Although case reports describing the mefloquine-in-
duced neuropsychiatric side effects are well documented,
the present case is unusual in that it documents symptoms
potentially associated with mefloquine greater than 4 years
after discontinuing the medication. Given the timing of the
patient’s initial symptoms relative to mefloquine exposure,
the type of symptoms, and lack of any other plausible
cause, a Naranjo assessment score of 6 was given to this
patient’s initial symptoms, indicating a probable relation-
ship with mefloquine exposure. The true etiology of his
progression of symptoms over the course of 4 years is more
difficult to ascertain. While it is probable he suffered from
mefloquine-induced toxicity during his deployment, the
contribution of the traumatic event to his post-deployment
behavioral changes, and the presence of other symptoms
(i.e. nightmares and insomnia), serve to confound the
diagnosis. The differential diagnosis includes persistent
PTSD and mal de debarquement syndrome. The significant
overlap in symptoms associated with mefloquine toxicity
and PTSD obscures the distinction between these diag-
noses. This patient exhibited behavioral symptoms in all
four PTSD diagnostic clusters used in the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V): re-experiencing, avoidance, negative cognitions
and mood, and arousal [17]. However, as reported in the
literature, the documented history of significant vestibular
dysfunction as evidence by the abnormal findings on
vestibular testing are more consistent with mefloquine
toxicity rather than PTSD or somatoform disorders such as
chronic subjective dizziness [18, 19]. A previous case
report of similar vertiginous symptoms after taking
mefloquine for prophylaxis also had objective evidence of
a central vestibulopathy [20]. An FDA investigation of
their Adverse Event Reporting System (FAERS), as well as
additional case reports, describe suspected mefloquine-in-
duced neuropsychiatric symptoms persisting and changing
over time, even after mefloquine has been discontinued
[21, 22]. A retrospective study examining mefloquine-re-
lated neuropsychiatric adverse events reported to a Danish
national register showed 30 and 48 % of subjects reported
experiencing nightmares and some form of cognitive dys-
function respectively, for at least 9 months [22]. This
supports the apparent finding in this case that mefloquine
toxicity symptoms can evolve and extend well beyond the
end of medication administration.
In addition to the overlap in symptoms, there exists
some contrasting biochemical links between mefloquine-
induced changes in the central nervous system (CNS) and
the development of PTSD [23]. It has been postulated that
three biochemical events (increase in markers of oxidative
stress, chronic inflammation, and excitotoxicity) play
roles in developing PTSD [23]. Mefloquine has also been
shown to increase levels of oxidative stress markers in the
CNS [24–26]. As a contrast, one of the proposed mech-
anisms behind mefloquine-induced neurotoxicity is gap
junction, specifically connexin 36, blockade. Connexin 36
forms the primary neuronal gap junction responsible for
intercellular communication, including glutamate trans-
mission [27]. Studies have shown that excessive gluta-
mate release and receptor overactivation can lead to
secondary neuronal death as well as PTSD [23, 28].
Pharmacologic blockade of connexin 36 can inhibit this
over-activation and subsequent neuronal death [29]. In a
mouse traumatic brain injury model, administration of a
single dose of mefloquine 10 min after trauma showed a
reduction in neuronal death compared with control mice
[30]. However, mefloquine by itself has also been linked
to neuronal cell death [31].
Some reports suggest that concomitant ethanol con-
sumption with mefloquine may have additive toxicity [32].
This patient reported alcohol intake while on shore leave
during the period he was taking mefloquine. Ethanol has
also been shown to inhibit connexin 36 gap junctions
connecting c-aminobutyric acid (GABA) neurons [33].
Although plausible, it is still unclear whether concomitant
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use of ethanol increases the risk, or severity, of mefloquine-
induced neuropsychiatric symptoms.
Another consideration in this case is the MTHFR
heterozygous C677T mutation. The MTHFR enzyme is
responsible for many functions, including folate metabo-
lism and DNA methylation, in addition to reducing
oxidative stress. Although some studies show a possible
link between this mutation and psychological disorders, the
literature is conflicting and no studies were found regarding
mefloquine or PTSD and MTHFR mutations [34, 35].
It is well known that thiamine deficiency can also cause
neurological signs and symptoms, both reversible and
irreversible; however, after weeks of thiamine replacement,
no improvement in symptomatology was observed in this
patient. In addition, although symptoms can be varied, the
patient did not exhibit the classic peripheral neuropathy or
Wernicke’s encephalopathy seen in dry beriberi. Interest-
ingly, it has been shown in vitro that mefloquine com-
pletely inhibits thiamine transport [36]. How, if at all, the
thiamine transport inhibition impacts mefloquine toxicity is
unclear.
In light of the extensive negative workup and lack of
reports linking mefloquine or PTSD with recurrent fevers,
it is difficult to link the febrile episodes to the patient’s
current symptomatology, and these may represent repeated
viral infections.
Conclusion
This case documents the potential long-term and varied
mefloquine-induced neuropsychiatric side effects, ranging
from a central vestibulopathy to significant behavioral
changes and sleep disorders. Especially pertinent to the
military population, it demonstrates the difficulty in dis-
tinguishing from possible mefloquine-induced toxicity
versus PTSD, and raises some questions regarding possible
linkages between the two diagnoses.
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